Elvitegravir, also known as GS-9137 ans EVG, is an integrase inhibitor used to treat HIV infection. The drug gained approval by the U.S. Food and Drug Administration on August 27, 2012 for use in adult patients starting HIV treatment for the first time as part of the fixed dose combination known as Stribild.
Douša M, Stach J, Gibala P, Lemr K. Quantification of structurally related aliphatic amino alcohols in l-valinol by hydrophilic interaction liquid chromatography separation combined with postcolumn derivatization and fluorescence detection. J Sep Sci. 2016 Mar;39(5):851-6. doi: 10.1002/jssc.201501302. Epub 2016 Jan 28. PubMed PMID: 26697727.
Rádl, Stanislav & Stach, Jan & Píša, Ondřej & Cinibulk, Josef & Havlíček, Jaroslav & Zajícová, Markéta & Pekárek, Tomas. (2015). An Improved Synthesis of Elvitegravir. Journal of Heterocyclic Chemistry. n/a-n/a. 10.1002/jhet.2477.
Sato M, Kawakami H, Motomura T, Aramaki H, Matsuda T, Yamashita M, Ito Y, Matsuzaki Y, Yamataka K, Ikeda S, Shinkai H. Quinolone carboxylic acids as a novel monoketo acid class of human immunodeficiency virus type 1 integrase inhibitors. J Med Chem. 2009 Aug 13;52(15):4869-82. doi: 10.1021/jm900460z. PubMed PMID: 19719237.
Sato M, Motomura T, Aramaki H, Matsuda T, Yamashita M, Ito Y, Kawakami H, Matsuzaki Y, Watanabe W, Yamataka K, Ikeda S, Kodama E, Matsuoka M, Shinkai H. Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J Med Chem. 2006 Mar 9;49(5):1506-8. PubMed PMID: 16509568.
Satoh, Motohide; Motomura, Takahisa; Matsuda, Takashi; Kondo, Kentaro; Ando, Koji; Matsuda, Koji; Miyake, Shuji; Uehara, Hideto. Preparation of stable crystals of a 4-oxoquinoline anti-HIV compound. WO 2005113508. (Assignee Japan Tobacco Inc., Japan)
Matsuda, Koji; Ando, Koji; Ohki, Shigeji; Yamasaki, Takahiro; Hoshi, Jun-Ichi. Process for production of highly pure quinolone compound. WO 2007063869. (Assignee Japan Tobacco Inc., Japan)
Dowdy, Eric; Chen, Xi; Pfeiffer, Steven. Process and intermediates for preparing 4-oxo-quinolone compounds from dimethoxybenzoic acid via cyclization reaction useful as HIV integrase inhibitors. WO 2008033836. (Assignee Gilead Sciences, Inc., USA)
Vellanki, Siva Rama Prasad; Dhake, Vilas Nathu; Ravi, Satyanarayana; Nuchu, Ravi; Puliyala, Ravindra; Shaik, Mahaboob Basha; Datta, Debashish. An improved process for the preparation of elvitegravir. WO 2011004389. (Assignee Matrix Laboratories Ltd., India)
Li, Jinliang; Zhao, Nan; Liu, Yu. Elvitegravir intermediates and preparation method and application thereof. CN 103819402. (Assignee Shanghai Desano Chemical Pharmaceutical Co., Ltd., Peop. Rep. China)
Rajan, Srinivasan Thirumalai; Eswaraiah, Sajja; Reddy, Ghojala Venkat; Reddy, Mallepally Venkat. Process for the preparation of elvitegravir and pharmaceutically acceptable salts and crystalline forms thereof. WO 2016193997 (Assignee MSN Laboratories Private Limited, India)
Ma, Shuai; Zhao, Jun; Du, Weihong; Cao, Shenghua. Synthesis of elvitegravir. Zhongguo Yiyao Gongye Zazhi. Sichuan Industrial Institute of Antibiotics. China National Pharmaceutical Group Co. Chengdu, Sichuan Province, Peop. Rep. China 610052. Volume 45. Issue 1. Pages 5-8. 2014.
